Fate Therapeutics Inc

2 wrz 2026, 19:46 UTC

Fate Therapeutics has begun the phase 2 RECLAIM-LN trial for FT819 in lupus nephritis, with the first patient dosed in an outpatient setting. Shares are higher.

1 wrz 2026, 23:16 UTC

Fate Therapeutics Inc shares are lower in after-market hours, reflecting broader market trends amid rising oil prices and inflation concerns.

31 sie 2026, 21:01 UTC

Fate Therapeutics Inc shares are lower in after-market hours, continuing a downward trend amid broader market sentiment influenced by hawkish Fed remarks.

26 sie 2026, 19:46 UTC

Fate Therapeutics shares are higher Wednesday, despite a pullback from earlier gains. No specific news was identified to explain the price movement.

24 sie 2026, 19:46 UTC

Fate Therapeutics Inc is trading higher amid broader market dynamics influenced by rising oil prices and geopolitical tensions, though no specific news was identified.

22 sie 2026, 00:02 UTC

Fate Therapeutics Inc shares are higher in after-market trading, reflecting broader market gains following recent pressures from rising crude oil prices and bond yields.

20 sie 2026, 20:06 UTC

Fate Therapeutics Inc is declining today, mirroring a broader market drop. The stock remains below its 20-day moving average and near its one-month low.

19 sie 2026, 19:26 UTC

Fate Therapeutics Inc shares are higher, supported by a significant rise in the ARK Genomic Revolution ETF during Wednesday's session.

14 sie 2026, 19:26 UTC

Fate Therapeutics has begun its Phase 2 RECLAIM-LN trial for FT819, targeting lupus nephritis. Shares are higher during Friday's session.

13 sie 2026, 23:36 UTC

Fate Therapeutics shares are higher in after-market hours, reflecting a recovery from earlier declines amid broader market optimism regarding the Federal Reserve's interest rate policy.

12 sie 2026, 21:02 UTC

Fate Therapeutics Inc. is gaining in after-market trading, rebounding from three consecutive sessions of declines. The price remains above the 20-day moving average.

7 sie 2026, 20:03 UTC

Fate Therapeutics shares are higher, reaching a session high amid rising U.S. Treasury yields and a weakening U.S. Dollar Index. No specific news identified.

6 sie 2026, 19:26 UTC

Fate Therapeutics Inc shares are lower today, reflecting broader market trends and a decline in the Russell 2000 Index amid ongoing inflation concerns.

5 sie 2026, 19:56 UTC

Fate Therapeutics shares are higher amid positive market sentiment and falling oil prices, despite some volatility during Wednesday's trading session.

4 sie 2026, 20:07 UTC

Fate Therapeutics is gaining as it announces employee inducement awards, including stock options at $2.45 per share. Shares rebounded after an earlier pullback.

3 sie 2026, 23:01 UTC

Fate Therapeutics Inc. shares are lower in after-market trading, despite stronger growth in the manufacturing sector and recent employee inducement awards.

29 lip 2026, 19:19 UTC

Fate Therapeutics is trading higher amid positive market momentum ahead of the Federal Reserve's monetary policy announcement, despite lingering inflation concerns.

28 lip 2026, 16:06 UTC

Fate Therapeutics shares are lower amid broader market weakness and investor caution ahead of key earnings reports and the Federal Reserve's interest rate decision.

27 lip 2026, 21:02 UTC

Fate Therapeutics shares are higher in after-market hours, despite no specific news. Broader market sentiment is improving with rising European equity indices.

24 lip 2026, 19:07 UTC

Fate Therapeutics shares are lower, pressured by a notable decline in first-quarter results and broader market sentiment. They remain below the 20-day moving average.

23 lip 2026, 21:11 UTC

Fate Therapeutics Inc. shares are higher in after-market hours, reflecting broader market gains. No specific company news has been identified to explain this increase.

22 lip 2026, 23:46 UTC

Fate Therapeutics Inc shares are higher in after-market trading, reflecting a modest gain since Wednesday's close, despite no specific news identified.

20 lip 2026, 18:26 UTC

Fate Therapeutics Inc. shares are effectively unchanged as trading remains flat. The stock has seen strong performance over the past month, nearing its recent highs.